[go: up one dir, main page]

PE20051150A1 - Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c - Google Patents

Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Info

Publication number
PE20051150A1
PE20051150A1 PE2005000220A PE2005000220A PE20051150A1 PE 20051150 A1 PE20051150 A1 PE 20051150A1 PE 2005000220 A PE2005000220 A PE 2005000220A PE 2005000220 A PE2005000220 A PE 2005000220A PE 20051150 A1 PE20051150 A1 PE 20051150A1
Authority
PE
Peru
Prior art keywords
hepatitis
virus
inhibitors
serine protease
compounds
Prior art date
Application number
PE2005000220A
Other languages
English (en)
Inventor
Viyyoor M Girijavallabhan
F George Njoroge
Francisco Velazquez
Raymond G Lovey
Siska Hendrata
Stephane L Bogen
Srikanth Venkatraman
Mousumi Sannigrahi
Ashok Arasappan
Kevin X Chen
Yi-Tsung Liu
Anil K Saksena
Yuhua Huang
Frank Bennett
Latha Nair
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20051150A1 publication Critical patent/PE20051150A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 ES OR8, NR9R10, CHR9R10; R8, R9 Y R10 PUEDEN SER IGUALES O DIFERENTES, SELECCIONANDOSE DE H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; A Y M SON CADA UNO R, OR, NHR, HALO, ENTRE OTROS; E ES CH, CR; L ES CH, CR, CH2CR, CRCH2; R, R2 Y R3 SON CADA UNO H, ALQUILO, HETEROALQUILO, ALQUENILO, ENTRE OTROS; Y ES 1, 2, ENTRE OTROS; G ES NH, O; R15, R17, R18 SON CADA UNO H, ALQUILO, ALQUENILO, ALQUINILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS A, B, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA SERINA PROTEASA NS3/NS4 DEL VIRUS DE LA HEPATITIS C (VHC) UTILES EN EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON VHC
PE2005000220A 2004-02-27 2005-02-24 Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c PE20051150A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54867004P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
PE20051150A1 true PE20051150A1 (es) 2006-01-16

Family

ID=34961556

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000220A PE20051150A1 (es) 2004-02-27 2005-02-24 Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Country Status (30)

Country Link
US (1) US8067379B2 (es)
EP (1) EP1730110B9 (es)
JP (1) JP4714732B2 (es)
KR (2) KR101316137B1 (es)
CN (2) CN101076516A (es)
AR (1) AR048241A1 (es)
AT (1) ATE470660T1 (es)
AU (1) AU2005222060A1 (es)
BR (1) BRPI0508085A (es)
CA (1) CA2557495C (es)
CY (1) CY1111212T1 (es)
DE (1) DE602005021760D1 (es)
DK (1) DK1730110T3 (es)
EC (1) ECSP066791A (es)
ES (1) ES2346233T3 (es)
HR (1) HRP20100416T1 (es)
IL (1) IL177544A (es)
MY (1) MY145081A (es)
NO (1) NO20064358L (es)
NZ (1) NZ549223A (es)
PE (1) PE20051150A1 (es)
PL (1) PL1730110T3 (es)
PT (1) PT1730110E (es)
RS (1) RS51394B (es)
RU (1) RU2428428C9 (es)
SG (1) SG186041A1 (es)
SI (1) SI1730110T1 (es)
TW (2) TWI314927B (es)
WO (1) WO2005087731A1 (es)
ZA (1) ZA200607096B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
US8067379B2 (en) * 2004-02-27 2011-11-29 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
CA2610167A1 (en) 2005-06-02 2006-12-07 Schering Corporation Administration of hcv protease inhibitors in combination with food to improve bioavailability
WO2006130687A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US7772178B2 (en) * 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
AU2006252623A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US20090220457A1 (en) * 2006-03-03 2009-09-03 Lahser Frederick C Combinations comprising hcv protease inhibitor(s) and hcv ires inhibitor(s), and methods of treatment related thereto
EP1993993A1 (en) 2006-03-16 2008-11-26 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
CA2647158C (en) * 2006-03-23 2012-07-31 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
BRPI0710878A2 (pt) 2006-04-11 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
CN101506167A (zh) 2006-08-17 2009-08-12 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
MX2009006056A (es) * 2006-12-07 2009-06-16 Schering Corp Formulacion de matriz sensible al ph.
JP5153648B2 (ja) * 2006-12-22 2013-02-27 住友精化株式会社 ３−ベンジルオキシベンゼンチオールの製造方法
KR20090094154A (ko) 2006-12-22 2009-09-03 쉐링 코포레이션 Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체
EP2081922B1 (en) 2006-12-22 2012-02-01 Schering Corporation 5,6-Ring annulated indole derivatives and use thereof
JP5211068B2 (ja) 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0815811A2 (pt) 2007-08-29 2015-02-18 Schering Corp Derivados de indol substituído e métodos de uso dos mesmos
BRPI0816116A2 (pt) 2007-08-29 2015-03-03 Schering Corp Derivados de indol 2,3-substituídos para o tratamento de infecções virais.
TW200911807A (en) 2007-08-29 2009-03-16 Schering Corp 2,3-substituted azaindole derivatives and methods of use thereof
CN101883590A (zh) 2007-09-14 2010-11-10 先灵公司 治疗丙型肝炎患者的方法
EP2205584A1 (en) * 2007-10-10 2010-07-14 Novartis Ag Spiropyrrolidines and their use against hcv and hiv infection
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
JP5416708B2 (ja) 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
NZ585370A (en) 2007-12-19 2012-09-28 Boehringer Ingelheim Int Viral polymerase inhibitors
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2303893B1 (en) 2008-06-13 2016-12-07 Merck Sharp & Dohme Corp. Tricyclic indole derivatives
EP2323631A1 (en) * 2008-08-07 2011-05-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CA2746258A1 (en) 2008-12-12 2010-06-17 Schering Corporation Deuterated compounds as hepatitis c virus (hcv) inhibitors
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
SG178115A1 (en) 2009-07-29 2012-03-29 Schering Corp ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF ß-AMINO-a- HYDROXY AMIDES
CA2782024A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
WO2011112429A1 (en) 2010-03-09 2011-09-15 Schering Corporation Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012073249A1 (en) 2010-12-01 2012-06-07 Arch Pharmalabs Limited A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs.
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
US20180273573A1 (en) * 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
WO2017059446A1 (en) * 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
EP3472130B1 (en) 2016-06-21 2022-02-16 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
EP3897667A4 (en) 2018-12-21 2023-04-19 Memorial Sloan Kettering Cancer Center SALICYL-ADENOSINE MONOSULFAMATE ANALOGS AND THEIR USES
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
WO2024153137A1 (zh) * 2023-01-17 2024-07-25 西藏海思科制药有限公司 一种手性氨基醇医药中间体的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133402T2 (de) * 1990-04-04 2004-11-11 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Protease von hepatitis-c-virus
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU757072B2 (en) 1997-08-11 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptide analogues
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PT1268519E (pt) 2000-04-03 2005-08-31 Vertex Pharma Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
SK14192002A3 (sk) 2000-04-05 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
PL358591A1 (en) 2000-04-19 2004-08-09 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
NZ523782A (en) * 2000-07-21 2005-10-28 Dendreon Corp Peptides as NS3-serine protease inhibitors of hepatitis C virus
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
EP1301527A2 (en) 2000-07-21 2003-04-16 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP4368581B2 (ja) * 2000-12-12 2009-11-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としてのジアリールペプチド
MXPA04003825A (es) * 2001-10-24 2004-07-08 Vertex Pharma Inhibidores de serina proteasa, en particular la ns3-ns4a proteasa del virus de hepatitis c, que incorpora un sistema de anillo fusionado.
US8067379B2 (en) * 2004-02-27 2011-11-29 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
US7772178B2 (en) 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same

Also Published As

Publication number Publication date
DK1730110T3 (da) 2010-09-27
IL177544A (en) 2015-02-26
RU2006134003A (ru) 2008-04-10
HRP20100416T1 (hr) 2010-09-30
TW200938526A (en) 2009-09-16
CN101076516A (zh) 2007-11-21
RS51394B (sr) 2011-02-28
CN103102389A (zh) 2013-05-15
AR048241A1 (es) 2006-04-12
SI1730110T1 (sl) 2010-10-29
KR101316137B1 (ko) 2013-10-10
CY1111212T1 (el) 2015-06-11
JP4714732B2 (ja) 2011-06-29
ECSP066791A (es) 2006-11-16
EP1730110A1 (en) 2006-12-13
RU2428428C9 (ru) 2012-03-10
US20070042968A1 (en) 2007-02-22
ATE470660T1 (de) 2010-06-15
AU2009225346A1 (en) 2009-11-05
NZ549223A (en) 2010-10-29
TWI314927B (en) 2009-09-21
CA2557495A1 (en) 2005-09-22
WO2005087731A8 (en) 2006-06-22
SG186041A1 (en) 2012-12-28
NO20064358L (no) 2006-11-24
KR20060134083A (ko) 2006-12-27
TWI393704B (zh) 2013-04-21
HK1095819A1 (en) 2007-07-27
ES2346233T3 (es) 2010-10-13
EP1730110B9 (en) 2011-11-02
PL1730110T3 (pl) 2010-11-30
TW200530183A (en) 2005-09-16
DE602005021760D1 (de) 2010-07-22
PT1730110E (pt) 2010-09-14
ZA200607096B (en) 2008-09-25
US8067379B2 (en) 2011-11-29
BRPI0508085A (pt) 2007-07-17
JP2007525514A (ja) 2007-09-06
KR20130018418A (ko) 2013-02-21
IL177544A0 (en) 2006-12-10
WO2005087731A1 (en) 2005-09-22
RU2428428C2 (ru) 2011-09-10
EP1730110B1 (en) 2010-06-09
AU2005222060A1 (en) 2005-09-22
CA2557495C (en) 2014-04-15
MY145081A (en) 2011-12-15

Similar Documents

Publication Publication Date Title
PE20051150A1 (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
PE20050940A1 (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
PE20050999A1 (es) Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
CY1107200T1 (el) Ενωσεις αναστολης της ηπατιτιδας c
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
PE20091237A1 (es) Derivados de pirrolidina como moduladores de serina proteasas
PE20050370A1 (es) Inhibidores peptidomimeticos novedosos de la serina proteasa ns3 del virus de la hepatitis c
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
ATE297946T1 (de) Inhibitoren von serin proteasen, speziell der hepatitis-c-virus ns3-protease
NO20062267L (no) Hepatitt C virus inhibitorer
PE20080457A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasas de hepatitis c
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
NO20062339L (no) Hepatitt C virus-inhibitoerer
DE602004029866D1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
PE20070364A1 (es) Compuestos macrociclicos como inhibidores de la proteasa ns3 del virus de la hepatitis c
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20030852A1 (es) Peptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
PE20080197A1 (es) Combinaciones que involucran el (los) inhibidor (es) de la proteasa del hcv, y metodos de tratamiento relacionado al (los) mismos(s)
PE20070804A1 (es) Compuestos heterociclicos como inhibidores de proteasa aspartica
PE20071222A1 (es) Compuestos heterociclos como inhibidores de la proteasa de serina del virus de la hepatitis c
PE20081312A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
TH86773A (th) ตัวยับยั้ง hcv ns3 โปรตีเอส
UY28168A1 (es) Inhibidores de las polimerasas virales

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed